相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway
Costanza Maria Cristiani et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells
Li Zhang et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2019)
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Taku Fujimura et al.
FRONTIERS IN MEDICINE (2019)
CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma
Rafael Samaniego et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
Taku Fujimura et al.
FRONTIERS IN ONCOLOGY (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
分享论文
